TCLF 2016

 
 
 

 

Combo can produce durable remissions in PTCL

Jen Smith Read Article
Published: 02/12/16

horowitz-steven-3-larry-young_230.jpg
Steven Horwitz, MD
Photo by Larry Young

A combination treatment regimen can produce durable remissions in patients newly diagnosed with peripheral T-cell lymphoma (PTCL), results of a phase 1 study suggest. The patients received brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisolone (BV+CHP). In some cases, this was followed by BV monotherapy. The estimated 3-year progression-free survival (PFS) for these patients was 52%, and the overall survival (OS) was 80%. [Read Article]

Chemo regimen can be ‘highly effective’ against ENKTL

Jen Smith Read Article
Published: 02/10/16

Huang_Huiqiang _LarryYoung_230.jpg
Hui-Qiang Huang, MD, PhD
Photo by Larry Young

A 3-agent chemotherapy regimen can be “highly effective” in patients with extranodal natural killer/T-cell lymphoma (ENKTL), according to researchers. In a single-center study, this regimen—pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX)—followed by extensive involved-field radiotherapy (EIFRT) produced high rates of long-term overall survival (OS) and progression-free survival (PFS) in newly diagnosed patients with stage I/II ENKTL. [Read Article]

Dual inhibitor could treat ATLL

Jen Smith Read Article
Published: 02/09/16

Yamagishi_Makoto_Credit_LarryYoung-230.jpg
Maokoto Yamagishi, PhD
Photo by Larry Young

Preclinical research suggests a compound that inhibits both EZH1 and EZH2 could be effective against adult T-cell leukemia/lymphoma (ATLL). The compound, known as OR-S1, has demonstrated activity against ATLL in vitro and in vivo. Researchers said OR-S1 reversed epigenetic disruption in ATLL cells, selectively eliminated both ATLL cells and cells infected with human T-cell leukemia virus type I (HTLV-1), and inhibited tumor growth in mouse models of ATLL. [Read Article]

Immunotherapy proves active against MF, SS

Jen Smith Read Article
Published: 02/05/16

Kim_Youn-LarryYoung-230.jpg
Youn Kim, MD
Photo by Larry Young

The PD-1-blocking antibody pembrolizumab can produce “significant objective clinical responses” in patients with relapsed or refractory cutaneous T-cell lymphoma, according to researchers. The drug elicited partial responses in 33% of patients enrolled in a phase 2 study. Half of the responders had mycosis fungoides (MF), and half had Sézary syndrome (SS). All responses are ongoing, and a few patients with stable disease . . . [Read Article]

Mutations may impact response to HDACis in PTCL-NOS

Jen Smith Read Article
Published: 02/04/16

Ji-Meng-Meng_LarryYoung_230.jpg
Meng-Meng Ji, MD, PhD
Photo by Larry Young

Preclinical research has revealed mutations that may affect the performance of histone deacetylase inhibitors (HDACis) in patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). The researchers identified histone-modifying gene mutations in patients with PTCL-NOS and found evidence to suggest these mutations confer shorter survival. The team also conducted experiments in Jurkat cells showing . . . [Read Article]

Lenalidomide shows promise for treating ATLL

Jen Smith Read Article
Published: 02/03/16

Nosaka_Kisato_LarryYoung-230.jpg
Kisato Nosaka, MD, PhD
Photo by Larry Young

Results of a phase 2 trial suggest lenalidomide may be a treatment option for patients with relapsed adult T-cell leukemia-lymphoma (ATLL). Lenalidomide produced a 42% overall response rate (ORR) in this trial, and patients had a “favorable” median overall survival, according to Kisato Nosaka, MD, PhD, of the National Center for Global Health and Medicine in Tokyo, Japan. He noted, however, that the survival data are still immature . . .  [Read Article]

Study suggests chidamide could treat rel/ref CTCL too

Jen Smith Read Article
Published: 02/02/16

Shi_Yuankai_LarryYoung-230.jpg
Yuankai Shi, MD, PhD
Photo by Larry Young

The oral histone deacetylase inhibitor chidamide can elicit responses in patients with relapsed or refractory cutaneous T-cell Lymphoma (CTCL), a new study suggests. Chidamide has already demonstrated efficacy against relapsed or refractory peripheral T-cell lymphoma and has been approved for this indication in China. Now, results of a phase 2 trial suggest chidamide might be a feasible treatment option for relapsed or refractory CTCL as well. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}